A couple more potential positives:

• Still awaiting CKD sub-study data on the eGFR changes, etc. I'm still curious why there absolutely no mention of this by DM on Monday. If indeed apabetalone elicits beneficial eGFR improvement in CKD patients, then this couples nicely with the 50% RRR for 3-point MACE in that same population.  
• More than a thousand other compounds in the BET inhibitor library with varying bromodomain specificities for BD1 vs. BD2 and BET protein specificities for BRD2, BRD3 and BRD4. Many of these have advanced in pre-clinical studies to be apabetalone follow on candidates with improved profile for the same indications that apabetalone is known for. Others have unique properties different than apabetalone and are being developed for entirely new clinical programs.